Impact of Factor V Leiden Mutation on Duration of Anticoagulation after a Single Thromboembolic Event

Thromb Haemost 1997; 77(02): 405
DOI: 10.1055/s-0038-1655978

Letter to the Editor

Schattauer GmbH Stuttgart

Authors

Claudia Rintelen

Medical Clinic I, Division of Haematology and Haemostaseology, Vienna, Austria
Ingrid Pabinger

Medical Clinic I, Division of Haematology and Haemostaseology, Vienna, Austria
Klaus Lechner

Medical Clinic I, Division of Haematology and Haemostaseology, Vienna, Austria
Christine Mann-halter

¹Department of Laboratory Medicine, Division of Molecular Biology, University Hospital Vienna, Vienna, Austria

References
1 Ridker PM. Leiden and recurrent venous thromboembolism. Thromb Haemos 1996; 76: 815-816
2 Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-232
3 Ridker PM, Miletich J, Goldhaber SZ, Stampfer MJ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboemblism. Circulation 1995; 92: 2800-2802
4 Eichinger S, Pabinger I, Stüpflen A, Hirschl L, Bialonczyk C, Forberg E, Schneider B, Rintelen C, Lechner K, Kyrle PA. The risk of recurrent venous thrombosis after discontinuation of oral anticoagulants in patients without and with factor V Leiden and the predictive value of a molecular marker of thrombosis. Blood 1995; 86 (Suppl. 01) 615a